Laboratory tests in primary care · by Dr Solange Déplanque and Dr Michaël Rochoy

Alopecia, hair loss

Dermatology · Symptom or situation · updated 2026-10-31

BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.

Frequency: Postpartum effluvium: about 20% of women, 2 to 3 months after delivery [1]; androgenetic alopecia: 30%, 40% and 50% of white men at ages 30, 40 and 50 [2]

Approach: what type of alopecia?

Laboratory tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

Do not order

Diffuse hair loss (telogen effluvium)

Laboratory tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

Do not order

Female androgenetic alopecia

Laboratory tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

Also consider

Men: androgenetic alopecia

Laboratory tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

Do not order

Alopecia areata (patchy hair loss)

Laboratory tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

Do not order

Child: patches of hair loss (tinea capitis)

Mycological examination (as soon as possible, without delaying treatment)

Contacts

Detailed explanation and international comparison (in French): read it in English (machine translation)

Also consider

Do not order

Scarring or inflammatory alopecia

Specialist opinion

Laboratory tests (only if the context requires)

Detailed explanation and international comparison (in French): read it in English (machine translation)

Also consider

Sources (22)
  1. Rebora A. Telogen effluvium: a comprehensive review. Clin Cosmet Investig Dermatol. 2019;12:583-590.
  2. Phillips TG, Slomiany WP, Allison R. Hair loss: common causes and treatment. Am Fam Physician. 2017;96(6):371-378.
  3. Murthy AB, Palaniappan V, Elango RR, Karthikeyan K. Moth-eaten alopecia and beyond: syphilitic alopecia – revisited. Indian J Sex Transm Dis AIDS. 2024;45(2):144-147.
  4. Centre de référence du lupus, SAPL et autres maladies auto-immunes rares ; centre de référence RAISE ; filière FAI²R. Protocole national de diagnostic et de soins (PNDS) : lupus systémique de l'adulte et de l'enfant. Haute Autorité de santé, janvier 2024.
  5. Mysore V, Parthasaradhi A, Kharkar RD, et al. Expert consensus on the management of androgenetic alopecia in India. Int J Trichology. 2019;11(3):101-106.
  6. Harries MJ, Ascott A, Asfour L, et al. British Association of Dermatologists living guideline for managing people with alopecia areata 2024. Br J Dermatol. 2025;192(2):190-205 (section 6.1, investigations).
  7. Harries MJ, Ahmed A, Ascott A, et al. British Association of Dermatologists living guideline for managing people with alopecia areata 2024 (mise à jour de 2025). Br J Dermatol 2026;194(2):e56-e73.
  8. Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : actes 1139 (25-OH-vitamine D), 2003 (zinc), 1802 (SDHEA), 1487 (anticorps anti-TPO).
  9. Mysore V, Parthasaradhi A, Kharkar RD, et al. Expert consensus on the management of telogen effluvium in India. Int J Trichology. 2019;11(3):107-112.
  10. Almohanna HM, Ahmed AA, Tsatalis JP, Tosti A. The role of vitamins and minerals in hair loss: a review. Dermatol Ther (Heidelb). 2019;9(1):51-70.
  11. Carmina E, Azziz R, Bergfeld W, et al. Female pattern hair loss and androgen excess: a report from the multidisciplinary Androgen Excess and PCOS Committee. J Clin Endocrinol Metab. 2019;104(7):2875-2891.
  12. Teede HJ, Tay CT, Laven J, Dokras A, Moran LJ, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Hum Reprod. 2023;38(9):1655-1679.
  13. Finastéride Biogaran 1 mg, comprimé pelliculé : résumé des caractéristiques du produit (rubriques 4.1 à 4.6). Base de données publique des médicaments, dernière mise à jour le 29/09/2026. (Propecia 1 mg : autorisation archivée.)
  14. Minoxidil Bailleul 5 %, solution pour application cutanée : résumé des caractéristiques du produit (rubriques 4.1 à 4.5). Base de données publique des médicaments, dernière mise à jour le 29/09/2026.
  15. Maruani A, Barbarot S, Gangneux JP, et al. Management of tinea capitis in children following the withdrawal of griseofulvin from the French market: a fast-track algorithm proposed by the Center of Evidence of the French Society of Dermatology. Ann Dermatol Venereol. 2022;149(4):238-240.
  16. Société française de dermatologie (centre de preuves), Société française de mycologie médicale, Société française de pédiatrie, Société française de dermatologie pédiatrique, SPILF. Teignes : algorithme de prise en charge des teignes de l'enfant après l'arrêt de la commercialisation de la griséofulvine en France. Élaboré en 2021, mis à jour en septembre 2026 (algorithme et bordereaux 1, 3, 4 et 5).
  17. Mayser P, Abeck D, Bosshard PP, et al. Consensus-based guideline on tinea capitis. J Dtsch Dermatol Ges. 2026;24(10):e1510-e1522.
  18. Agence nationale de sécurité du médicament et des produits de santé (ANSM). Traitement de la teigne de l'enfant et indisponibilité de la griséofulvine : l'ANSM précise la conduite à tenir. Publié le 9 juillet 2021, mis à jour le 4 juin 2026.
  19. Gangneux JP, Brun S, Menotti J, Botterel F. Role of the mycological diagnosis in the management of tinea capitis: French recommendations in the post-griseofulvin era. J Mycol Med. 2023;33(3):101379.
  20. Hôpitaux universitaires de Strasbourg, plateau technique de microbiologie. Prélèvement de peau ou de phanères pour examen mycologique avec recherche de dermatophytes. Mode opératoire PTM-R2-MOPE-038, version 3, applicable le 7 juillet 2026.
  21. Ely JW, Rosenfeld S, Seabury Stone M. Diagnosis and management of tinea infections. Am Fam Physician. 2014;90(10):702-710.
  22. Yongpisarn T, Tejapira K, Suchonwanit P. Comorbidities in primary cicatricial alopecia: a systematic review and meta-analysis. Front Immunol. 2025;16:1516407.